1. Home
  2. BIO vs RGEN Comparison

BIO vs RGEN Comparison

Compare BIO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

HOLD

Current Price

$277.40

Market Cap

7.1B

Sector

Industrials

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$119.75

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIO
RGEN
Founded
1952
1981
Country
United States
United States
Employees
7450
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.6B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
BIO
RGEN
Price
$277.40
$119.75
Analyst Decision
Buy
Buy
Analyst Count
4
11
Target Price
$339.75
$172.91
AVG Volume (30 Days)
282.4K
827.6K
Earning Date
04-30-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
286.96
EPS
N/A
0.86
Revenue
N/A
$141,236,000.00
Revenue This Year
$2.59
$14.30
Revenue Next Year
$3.21
$14.52
P/E Ratio
$9.72
$139.53
Revenue Growth
N/A
35.10
52 Week Low
$211.43
$109.66
52 Week High
$343.12
$175.77

Technical Indicators

Market Signals
Indicator
BIO
RGEN
Relative Strength Index (RSI) 52.60 49.60
Support Level $256.85 $111.29
Resistance Level $289.61 $131.81
Average True Range (ATR) 7.87 4.70
MACD 1.42 1.58
Stochastic Oscillator 61.26 79.74

Price Performance

Historical Comparison
BIO
RGEN

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: